Fig. 6
In vivo antitumor activity of GD2/CAR-T cells. a MMYC-3 and AMYC-5 patient-derived xenografts received different treatments: group A, PBS (i.v.); group B, non-transduced T cells (i.v.);group C, non-transduced T cells (i.t.); group D, GD2.BBζ CAR-T cells (i.v.); and group E, GD2.BBζ CAR cells (i.t.). The results are expressed as the mean tumor volume (mm3) ± SD with n = 5 for all groups. b Quantification of T cells within the blood on eight and 15 days after adoptive transfer into mice: group B, non-transduced T cells (i.v.);group C, non-transduced T cells (i.t.); group D, GD2.BBζ CAR-T cells (i.v.); and group E, GD2.BBζ CAR cells (i.t.). c Exhaustion marker expression of GD2.BBζ CAR-T cells on day 14 after adoptive transfer of T cells: group B, non-transduced T cells (i.v.);group C, non-transduced T cells (i.t.); group D, GD2.BBζ CAR-T cells (i.v.); and group E, GD2.BBζ CAR cells (i.t.). d Quantification of T cells within the spleen and tumor 15 days after adoptive transfer of T cells in MMYC-3: group B, non-transduced T cells (i.v.);group C, non-transduced T cells (i.t.); group D, GD2.BBζ CAR-T cells (i.v.); and group E, GD2.BBζ CAR cells (i.t.). e Quantification of T cells within the spleen and tumor 15 days after adoptive transfer of T cells in AMYC-5: group B, non-transduced T cells (i.v.); group C, non-transduced T cells (i.t.); group D, GD2.BBζ CAR-T cells (i.v.); and group E, GD2.BBζ CAR cells (i.t.). f The GD2 expression of tumors on 15 days after adoptive transfer of 107 T cells: group B, non-transduced T cells (i.v.); group C, non-transduced T cells (i.t.); group D, GD2.BBζ CAR-T cells (i.v.); and group E, GD2.BBζ CAR cells (i.t.). *P < 0.05 by Student’s t test